BeiGene Announces Initiation of First Pivotal Study in China with BTK Inhibitor BGB-3111
March 02, 2017 09:00 ET
|
BeiGene, LTD.
BEIJING, March 02, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing molecularly-targeted and immuno-oncology drugs for the treatment of...
BeiGene Initiates Global Phase III Trial of the BTK Inhibitor BGB-3111 in Waldenström’s Macroglobulinemia
January 25, 2017 08:00 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass., Jan. 25, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE) a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncology drugs for...
BeiGene Presents Updated Clinical Data on BTK Inhibitor BGB-3111 in Patients with Waldenström’s Macroglobulinemia at the 2016 American Society of Hematology Annual Meeting
December 05, 2016 22:00 ET
|
BeiGene, LTD.
WALTHAM, Mass., Dec. 05, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE) a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncology drugs for...
BeiGene Presents Updated Clinical Data on BTK Inhibitor BGB-3111 in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia at the 2016 American Society of Hematology Annual Meeting
December 05, 2016 11:15 ET
|
BeiGene, LTD.
WALTHAM, Mass, Dec. 05, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE) a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncology drugs for the...
BeiGene Announces Oral Presentations on BTK Inhibitor BGB-3111 at the 2016 American Society of Hematology Annual Meeting
November 03, 2016 09:00 ET
|
BeiGene, LTD.
WALTHAM, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE) (“BeiGene”), a clinical-stage biopharmaceutical company developing molecularly-targeted and immuno-oncology drugs for...
BeiGene Presents Updated Clinical Data on BTK Inhibitor BGB-3111 in Patients with Waldenstrom’s Macroglobulinemia at 9th International Workshop on Waldenstrom’s Macroglobulinemia
October 07, 2016 09:45 ET
|
BeiGene, LTD.
WALTHAM, Mass., Oct. 07, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncological drugs for...
BeiGene to Host Conference Call on BGB-3111 Data Presentation at IWWM-9
October 04, 2016 16:15 ET
|
BeiGene, LTD.
WALTHAM, Mass., Oct. 04, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing molecularly-targeted and immuno-oncological drugs for the...